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PtdIns(3,4,5)P3-dependent Rac exchanger 1 (PREX1) is a Rac-
guanine nucleotide exchange factor (GEF) overexpressed in a sig-
nificant proportionofhumanbreast cancers that integrates signals
fromupstreamErbB2/3 andCXCR4membrane surface receptors.
However, the PREX1 domains that facilitate its oncogenic activity
and downstream signaling are not completely understood. We
identify that ERK1/2MAPK acts downstream of PREX1 and con-
tributes to PREX1-mediated anchorage-independent cell growth.
PREX1 overexpression increased but its shRNA knockdown
decreased ERK1/2 phosphorylation in response to EGF/IGF-1
stimulation, resulting in inductionof thecell cycleregulatorscyclin
D1 and p21WAF1/CIP1. PREX1-mediated ERK1/2 phosphorylation,
anchorage-independent cell growth, and cell migration were sup-
pressed by inhibition of MEK1/2/ERK1/2 signaling. PREX1 over-
expression reduced staurosporine-induced apoptosis whereas its
shRNAknockdown promoted apoptosis in response to staurospo-
rine or the anti-estrogen drug tamoxifen. Expression of wild-type
but not GEF-inactive PREX1 increased anchorage-independent
cell growth. In addition, mouse xenograft studies revealed that
expression of wild-type but not GEF-dead PREX1 resulted in the
formation of larger tumors that displayed increased phosphoryla-
tion of ERK1/2 but not AKT. The impaired anchorage-indepen-
dent cell growth, apoptosis, and ERK1/2 signaling observed in
stable PREX1 knockdown cells was restored by expression of
wild-type but not GEF-dead-PREX1. Therefore, PREX1-Rac-
GEF activity is critical for PREX1-dependent anchorage-inde-
pendent cell growth and xenograft tumor growth and may
represent a possible therapeutic target for breast cancers that
exhibit PREX1 overexpression.
The Rac proteins (Rac1, Rac2, and Rac3) are a subgroup of
the Rho-GTPase family that regulate cell motility and, when
deregulated, drive cancer invasion and metastasis (1–3). Rac
proteins undergo rapid and spatiotemporally coordinated
cycles of activation and inactivation linked to upstream recep-
tor signaling by guanine nucleotide exchange factors (GEFs)2
(4). The most common mechanism for Rac hyperactivation in
human cancer is via dysregulation of Rac-GEF activity. PtdIns
(3,4,5)P3-dependent Rac exchanger 1 (PREX1) is a member of
the Dbl family of Rho-GEFs that promotes chemoattractant-
stimulated neutrophil chemotaxis and reactive O2 species for-
mation (5–7). PREX1 is amultidomain protein that contains an
N-terminal catalytic Dbl-homologous (DH) domain, which
activates Rac, adjacent to a pleckstrin homology (PH) do-
main, which binds to and is activated by PI3K-generated
PtdIns(3,4,5)P3, followed by two dishevelled, EGL-10 and
pleckstrin (DEP) domains, two PDZ domains, and a catalyti-
cally inactiveC-terminal inositol polyphosphate 4-phosphatase
(IP4P) domain, which shares 30% amino acid identity with the
catalytically active IP4P domain of the inositol polyphosphate
4-phosphatases INPP4Aand INPP4B (5, 8, 9). The IP4Pdomain
of PREX1 contains a common catalytic CX5R motif shared by
dual specificity phosphoinositide phosphatases; however,
PREX1 does not exhibit phosphatase activity for unknown rea-
sons (5). PREX1 is synergistically activated by PtdIns(3,4,5)P3
generated by PI3K and the  subunits of G-protein-coupled
receptors (5, 8).
PREX1 and the related PREX2 were recently identified as
putative oncogenes in human cancers (10–14). The human
PREX1 gene is located on chromosome 20q13, and amplifica-
tion of this region occurs in 8–29% of breast tumors associated
with a poor prognosis (10). This region is also frequently
deleted or amplified in malignant myeloid diseases (15), hered-
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itary prostate cancer (16), pancreatic endocrine tumors (17),
and ovarian cancers (18). PREX1 expression is not detected in
the normal breast; however, the PREX1 gene is amplified in
primary breast tumors, with PREX1-positive staining observed
by immunohistochemistry in 58% of breast cancers (10). In par-
ticular PREX1 mRNA and protein levels are up-regulated in
ER/luminal breast tumors (10, 19). Higher PREX1 mRNA
expression has also been reported in ErbB2 tumors in one
study (10). In breast cancer cells, neuregulin activation of ErbB
receptors results in PREX1 phosphorylation, increasing its Rac-
GEF activity (11). PREX1 converges signals from ErbB recep-
tors and G-protein-coupled receptors. Ectopic PREX1 expres-
sion in cultured cells promotes cell viability, migration, and
invasion (19, 20). In contrastPREX1 shRNAknockdown in ER
breast cancer cells results in reduced cell migration, prolifera-
tion, anchorage-independent cell growth, and xenograft tumor
growth (10, 11). Although there is compelling evidence that
PREX1 expression is increased in some breast cancer subsets
and that its activation is driven byG-protein-coupled receptors
and PI3K signaling (10, 11), there is very little data that reveal
the mechanism of oncogenic PREX1 signaling.
Here we demonstrate that PREX1 increases cell prolifera-
tion, migration, anchorage-independent cell growth, and xeno-
graft tumor growth by promoting ERK1/2 activation and that
inhibition of ERK1/2 signaling suppresses PREX1 effects.
PREX1-mediated breast cancer cell growth/survival under
anchorage-independent conditions and xenograft tumor
growth are critically dependent on its Rac-GEF activity, which
activates ERK1/2. These studies therefore suggest that inhibi-
tion of PREX1 Rac-GEF activity may represent a therapeutic
strategy for treatment of breast tumors that exhibit PREX1
overexpression.
Results
PREX1 Regulates ERK1/2 Signaling in Both ER and ER
Breast Cancer Cell Lines—EGF, IGF-1, and the ErbB2/3 ligand
heregulin activate Rac1 in many breast cancer cell lines (10,
21–24). To investigate the signaling pathways regulated by
PREX1 that promote cell proliferation and survival, MDA-MB-
231-luc-D3H1 cells, an ER basal breast cancer cell line that
does not exhibit PREX1 protein expression (10), were stably
transduced to express full-length PREX1, which was N-termi-
nally tagged with HA (Fig. 1A). MDA-MB-231-luc-D3H1 cells
expressedHA-PREX1 at similar levels as endogenous PREX1 in
ERMCF-7-luc-F5 breast cancer cells (Fig. 1A). In response to
EGF stimulation, AKT phosphorylation (Ser473) was increased
in MDA-MB-231-luc-D3H1 cells expressing PREX1 relative to
vector controls, but this was not statistically significant (Fig. 1,
B and C). However, a significant increase in ERK1/2 phosphor-
ylation (Thr202/Thr204)was observed for up to 30min after EGF
stimulation in cells expressing PREX1 relative to vector con-
trols (Fig. 1, B and D), and this was suppressed by treatment
with a small molecule MEK1/2 inhibitor, U0126, which blocks
downstream ERK1/2 activation (25, 26) (Fig. 1, E and F). To
confirm that endogenous PREX1 regulates ERK1/2 activation,
two distinct shRNA interference sequenceswere utilized to sta-
bly knock down endogenous PREX1 inERMCF-7-luc-F5 cells
that express PREX1 (10), and75% knockdown was achieved,
as determined by PREX1 immunoblot (Fig. 2, A and B) and
mRNA analysis (Fig. 2C). IGF-1 (10 ng/ml)-induced ERK1/2
phosphorylation was significantly reduced in PREX1-depleted
cells (Fig. 2, D and E). PREX1 expression promotes AKT acti-
vation in response to IGF-1 (10 or 100 ng/ml) stimulation in
MCF-7 cells (19); however, no significant change in AKT phos-
phorylation (Ser473 and Thr308) was demonstrated at the con-
centration of IGF-1 used in our studies (10 ng/ml), although a
trend toward decreased phosphorylation was observed (Fig. 2,
F–H). These data suggest that PREX1 enhances ERK1/2 activa-
tion following EGF stimulation of ER or low-dose IGF-1 stim-
ulation of ER breast cancer cells.
PREX1-mediated ERK1/2Activation IsDependent on Its Rac-
GEFActivity—PREX1 contains anN-terminal catalytic DH-PH
domain, two DEP domains, two PDZ domains, and a C-termi-
nal,350-amino acid region (IP4P domain) that shares30%
amino acid identity to the PtdIns(3,4)P2 4 phosphatases
INPP4A and INPP4B (5, 8, 9) (Fig. 3A). The PREX1 N-terminal
PH domain binds to and is activated by PtdIns(3,4,5)P3,
whereas the DH domain binds and activates Rac. The DH-PH
domain is required for maximal Rac-GEF activity (5, 8), but to
date the PREX1 domain(s) that facilitate its oncogenic signaling
are unknown. To dissect the molecular mechanisms by which
PREX1 enhances ERK1/2 activity, we stably expressed con-
structs encoding wild-type HA-tagged PREX1 (HA-PREX1),
PREX1 that lacks the IP4P domain (HA-4P-PREX1, amino
acids 36–1364), the isolated IP4P domain (HA-4P-PREX1,
amino acids 791–1659), or a PREX1 (E56A/N238A) “GEF-
dead”mutant (GEF-deadHA-PREX1, Ref. 8) (Fig. 3A) inPREX1
shRNA-depletedMCF-7-luc-F5 cells. Reconstitution of PREX1
knockdown with wild-type HA-PREX1 restored ERK1/2 phos-
phorylation to levels observed in control shRNA cells following
low-dose IGF-1 stimulation (10 ng/ml) (Fig. 3, B and C), which
was also observed with expression of HA-4P-PREX1 but not
HA-4P-PREX1 (Fig. 3, B and C). Notably, expression of GEF-
dead HA-PREX1 was unable to restore ERK1/2 phosphoryla-
tion to the levels observed in control shRNA cells or in PREX1
shRNA cells expressing wild-type HA-PREX1 (Fig. 3, B and C),
indicating that PREX1 Rac-GEF activity is critical for its activa-
tion of ERK1/2. In control studies, all PREX1 mutants were
expressed at comparable or higher levels relative to wild-type
PREX1 expression in PREX1 shRNA cells, as assessed by
anti-HA immunoblot (Fig. 3B).
PREX1 Regulates Cell Proliferation and Cyclin D1 and
p21WAF1/CIP1 Expression—ERK1/2 regulates G1-S phase pro-
gression by stimulating the transcription of the proto-oncogene
cyclin D1 (27, 28). Cyclin D1 enhances G1-S phase progression
by forming a complex with cyclin-dependent kinase (Cdk) 4
and Cdk6 (29). The cyclin D1-Cdk4/6 complex phosphorylates
and inactivates the retinoblastoma protein, resulting in activa-
tion of the E2F transcription factor. E2F then, in turn, activates
various genes required for cell cycle progression from G1 to S
phase (30). ERK1/2 also regulates G1-S phase progression by
modulating the expression of Cdk inhibitors, including
p21WAF1/CIP1 and p27KIP1. Mitogen-induced ERK1/2 activa-
tion leads to the transient accumulation of p21WAF1/CIP1 in
earlyG1 phase (31, 32). Cells withPREX1 shRNAknockdownor
overexpression showed reduced or enhanced cell proliferation,
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respectively, after 72 h, as demonstrated by 3-(4,5-dimethylthi-
azol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) assays (Fig.
4, A and B). Additionally, EGF-stimulated expression of cyclin
D1 and p21WAF1/CIP1 was enhanced in PREX1-overexpressing
cells (Fig. 4, C–E). In contrast, PREX1 shRNA knockdown
reduced cyclin D1 and p21WAF1/CIP1 proteins levels in response
to low-dose IGF-1 (10 ng/ml) stimulation (Fig. 4, F–H).
PREX1 Regulates Staurosporine/Tamoxifen-induced Apo-
ptosis—To reveal the role PREX1 plays in regulating cell death,
cells were treated with staurosporine, a potent stimulus fre-
quently used to induce apoptosis inmammalian cells, including
MCF-7 and MDA-MB-231 breast cancer cell lines (33–35).
PREX1 overexpression in MDA-MB-231-luc-D3H1 cells sig-
nificantly reduced the number of apoptotic cells (TUNEL-pos-
itive) (Fig. 5A) following staurosporine treatment associated
with decreased cleavage of caspase-3 and poly (ADP-ribose)
polymerase I (PARP) (Fig. 5, B–D). PREX1 regulation of stau-
rosporine-induced apoptosis was confirmed in stable PREX1
shRNA knockdown cells. PREX1 depletion in MCF-7-luc-F5
cells was associatedwith increased staurosporine-mediated cell
death (Fig. 5E). MCF-7 cells do not express caspase-3; there-
fore, only PARP cleavagewas assessed. Following staurosporine
treatment, PREX1 depletion decreased intact PARP levels asso-
ciated with the appearance of cleaved PARP (Fig. 5, F and G).
FIGURE 1. Overexpression of PREX1 enhances ERK1/2 but not AKT phosphorylation in MDA-MB-231-luc-D3H1 cells. A, MDA-MB-231-luc-D3H1 cells
stably transducedwith control vector, HA-PREX1, or GEF-deadHA-PREX1 and parental MCF-7-luc-F5 cells were analyzed by immunoblotting using HA, PREX1,
or GAPDH antibodies. Normalized PREX1 protein expression relative to endogenous PREX1 levels in MCF-7-luc-F5 cells is shown below. B, cells were serum-
starved for 24 h and then stimulated with 100 ng/ml EGF for the indicated time periods. Cell lysates were immunoblotted using HA, pAKTThr-308, pAKTSer-473,
AKT, pERK1/2, or ERK1/2 antibodies. C and D, data are presented as mean -fold change in pAKTSer-473/AKT (C) or pERK1/2/ERK1/2 (D) S.E. relative to control
vector at 0 min EGF stimulation, which was assigned an arbitrary value of 1 (n  3). E, cells were serum-starved for 24 h, treated with 1 M U0126 (MEK1/2
inhibitor), and stimulated with 100 ng/ml EGF for 15 min. Cell lysates were immunoblotted using HA, pERK1/2, ERK1/2, or -actin antibodies. F, data are
expressed as mean -fold change in pERK1/2/ERK1/2 S.E. relative to DMSO-treated control vector at 0 min EGF stimulation, which was assigned an arbitrary
value of 1 (n 3). *, p	 0.05; **, p	 0.01; ***, p	 0.001.
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PREX1 knockdown did not promote PARP cleavage in the
absence of staurosporine treatment, suggesting that PREX1
regulates apoptosis in response to extrinsic signals. The ele-
vated cell death induced by staurosporine observed in PREX1
knockdown MCF-7-luc-F5 cells was rescued by reconstitution
of wild-type HA-PREX1 or HA-4P-PREX1 but not GEF-dead
HA-PREX1 (Fig. 5H), indicating that PREX1 Rac-GEF activity
is critical for PREX1 regulation of staurosporine-induced apo-
ptosis in breast cancer cells. Apoptosis can be induced in ER
MCF-7 breast cancer cells by treatment with tamoxifen, a
FIGURE 2. PREX1 knockdown decreases ERK1/2 but not AKT phosphorylation in MCF-7-luc-F5 cells. A, cells stably transduced with two different PREX1
shRNA (PREX1 shRNA (1) and PREX1 shRNA (2)) or a non-target control shRNA were analyzed by immunoblotting using PREX1 or -actin antibodies. B,
densitometric values of PREX1expression are shownasmean S.E. relative to control shRNA,whichwas assigned an arbitrary valueof 1 (n3).C, quantitative
RT-PCR analysis of PREX1mRNA normalized toGAPDH fromMCF-7-luc-F5 cells stably expressing control shRNA, PREX1 shRNA (1), or PREX1 shRNA (2). Data are
presented asmean -fold difference S.E. relative to control shRNA, whichwas assigned an arbitrary value of 1 (n 3).D, cells were serum-starved for 24 h and
then stimulated with 10 ng/ml IGF-1 for the indicated time periods. Cell lysates were immunoblotted using PREX1, pERK1/2, or ERK1/2 antibodies. E, data are
expressed asmean -fold change in pERK1/2/ERK1/2 S.E. relative to control shRNA at 0min IGF-1 stimulation, whichwas assigned an arbitrary value of 1 (n
3). F, cells were serum-starved for 24 h and then stimulated with 10 ng/ml IGF-1 for the indicated time periods. Cell lysates were immunoblotted using PREX1,
pAKTSer-473, pAKTThr-308, or AKT antibodies. G and H, data are expressed as mean -fold change in pAKTSer-473/AKT (G), pAKTThr-308/AKT (H)  S.E. relative to
control shRNA at 0 min IGF-1 stimulation, which was assigned an arbitrary value of 1 (n 3). *, p	 0.05; **, p	 0.01; ***, p	 0.001.
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widely used anti-estrogen drug. PREX1 knockdown signifi-
cantly increased the number of apoptotic cells in response
to tamoxifen treatment compared with control shRNA cells
(Fig. 5I).
PREX1 Mediates Anchorage-independent Cell Growth via
ERK1/2—To determine whether PREX1 regulates cell growth/
survival under anchorage-independent conditions, soft agar
assays were undertaken using MDA-MB-231-luc-D3H1 cells
overexpressingwild-type orGEF-dead PREX1 (Fig. 1A). PREX1
overexpression significantly increased the number of colonies
formed compared with vector controls (Fig. 6, A and B).
Although GEF-dead HA-PREX1 overexpression marginally
increased colony formation comparedwith control vector cells,
expression of PREX1 lacking Rac-GEF activity did not enhance
anchorage-independent cell growth to the levels observed in
wild-type HA-PREX1 cells (Fig. 6, A and B). Previous studies
have independently reported that ERK1/2 or PREX1/Rac1 pro-
motes anchorage-independent growth of breast cancer cells
(10, 36, 37). To determinewhether PREX1 promotes anchorage
independent colony formation via Rac1-ERK1/2, soft agar stud-
ies were undertaken in MDA-MB-231-luc-D3H1 cells overex-
pressing PREX1 in the presence of aMEK1/2 inhibitor (U0126),
Rac1 inhibitor (NSC23766), or DMSO (vehicle). Colony forma-
tion was significantly reduced in a dose-dependent manner in
PREX1-overexpressing cells in the presence of NSC23766 (Fig.
6, C and D). Furthermore, treatment with U0126 significantly
reduced colony formation in HA-PREX1-overexpressing cells
to the levels observed in control cells (Fig. 6, E and F). There-
fore, PREX1-enhanced anchorage-independent cell growth
is dependent on Rac1 and ERK1/2. In contrast, PREX1
shRNA knockdown reduced the number of colonies formed
in soft agar, as reported previously (Fig. 6, G and H) (10, 11).
The impaired anchorage-independent cell growth observed
in stable PREX1 knockdown cells was restored by expression
of wild-type HA-PREX1 but not GEF-dead HA-PREX1 (Fig.
6, G and H), indicating that the ability of PREX1 to promote
anchorage-independent cell growth is dependent on its Rac-
GEF activity.
PREX1 Promotes Cell Migration via ERK1/2—PREX1 and
ERK1/2 have both been independently shown to promote can-
cer cell migration (10, 13, 38, 39). Our results suggest that
ERK1/2 signaling is an important downstream mediator of
PREX1 function in breast cancer cells. We therefore investi-
gated whether ERK1/2 signaling contributes to PREX1-me-
diated cell migration using Transwell Boyden chamber
migration assays. Overexpression of PREX1 in MDA-MB-
231-luc-D3H1 cells significantly enhanced the migration of
cells toward 10% serum relative to vector controls (Fig. 6, I
and J). Inhibition of ERK1/2 activity using U0126 signifi-
cantly suppressed the migration of PREX1-overexpressing
FIGURE 3. Reconstitution of wild-type but not GEF-dead-PREX1 restores ERK1/2 activation in PREX1 knockdown MCF-7-luc-F5 cells. A, schematic of
PREX1 constructs: full-length wild-type PREX1 (HA-PREX1), the PREX1 mutant lacking the IP4P domain but containing DH/PH/DEP-DEP/PDZ-PDZ (HA-4P-
PREX1), the PREX1 mutant containing only the IP4P domain (HA-4P-PREX1), and the PREX1 (E56A/N238A) GEF-dead mutant (GEF-dead HA-PREX1). B, stable
MCF-7-luc-F5 cells expressing control shRNA, PREX1 shRNA (2), PREX1 shRNA (2) HA-PREX1, PREX1 shRNA (2) HA-4P-PREX1, PREX1 shRNA (2) HA-4P-
PREX1, or PREX1 shRNA (2) GEF-dead HA-PREX1 were serum-starved for 24 h and then stimulated with 10 ng/ml IGF-1 for the indicated time periods. Cell
lysates were immunoblotted using PREX1, HA, pERK1/2, ERK1/2, or -actin antibodies. Normalized PREX1 protein expression relative to endogenous PREX1
levels in MCF-7-luc-F5 control shRNA cells at 0 min IGF-1 stimulation is shown below. C, data are expressed as mean -fold change in pERK1/2/ERK1/2 S.E.
relative to control shRNA at 0 min IGF-1 stimulation, which was assigned an arbitrary value of 1 (n 3). *, p	 0.05.
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cells to the levels observed in vehicle-treated vector controls
(Fig. 6, I and J), indicating that inhibition of ERK1/2 activity
is sufficient to disrupt the enhanced migratory capacity
induced by PREX1 overexpression.
PREX1 Promotes Xenograft Tumor Growth—To determine
the effects of PREX1 overexpression on tumorigenesis in vivo,
we conducted xenograft studies in nude mice. MDA-MB-231-
luc-D3H1 cells overexpressing wild-type or GEF-dead PREX1
or vector controls (Fig. 7A) were injected into the inguinal
mammary fat pads of BALB/c nudemice, and orthotopicmam-
mary xenograft growth was analyzed 12 days after surgery.
Although PREX1 shRNA-mediated depletion has been
reported to suppress xenograft tumor growth (10, 11), the
effects of PREX1 overexpression, which recapitulates the
increased expression observed in some human breast cancers,
has not been reported. Wild-type, but not GEF-dead, PREX1
overexpression significantly increased the growth of xenograft
tumors formed by MDA-MB-231-luc-D3H1 cells compared
with vector controls (Fig. 7, B–D). Histopathological analysis
demonstrated increased cell proliferation and reduced cell
death, as shown by Ki-67 and cleaved caspase-3 staining,
respectively, in PREX1-overexpressing tumors (Fig. 7, E–G).
PREX1-overexpressing tumors also showed evidence of
increased expression of activated (phosphorylated) ERK1/2
relative to controls, as shown by phosphospecific antibody
staining; however, no change in the intensity of pAKTSer-473
FIGURE 4. PREX1 regulates cell proliferation and cyclin D1/p21WAF1/CIP1 induction. A and B, MTT proliferation assays were performed on stable MDA-MB-
231-luc-D3H1 cells expressing control vector or HA-PREX1 (A) or stable MCF-7-luc-F5 cells expressing control shRNA, PREX1 shRNA (1), or PREX1 shRNA (2) (B).
Data points represent the relativemean cell proliferation S.E. relative to control, whichwas assigned an arbitrary value of 1 (n 5).C, MDA-MB-231-luc-D3H1
cells were serum-starved for 24 h and then stimulatedwith 100 ng/ml EGF for the time periods as indicated. Cell lysates were immunoblotted using HA, cyclin
D1, p21WAF1/CIP1, or-actin antibodies.D and E, densitometric values of cyclinD1 (D) or p21WAF1/CIP1 (E) were normalized to-actin. Data are expressed asmean
-fold difference  S.E. relative to control vector at 0 min EGF stimulation, which was assigned an arbitrary value of 1 (n  3). F, MCF-7-luc-F5 cells were
serum-starved for 24 h and then stimulated with 10 ng/ml IGF-1 for the indicated time periods. Cell lysates were immunoblotted using PREX1, cyclin D1,
p21WAF1/CIP1, or -actin antibodies. G and H, densitometric values of cyclin D1 (G) or p21WAF1/CIP1 (H) were normalized to -actin. Data are expressed as mean
-fold difference S.E. relative to control shRNA at 0 min EGF stimulation, which was assigned an arbitrary value of 1 (n 3). *, p	 0.05; **, p	 0.01; ***, p	
0.001.
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antibody staining was observed (Fig. 7, E and H). In contrast,
PREX1 shRNA knockdown MCF-7-luc-F5 cell xenografts in
mammary fat pads showed a reduced rate of tumor growth
compared with control shRNA tumors; however, tumor
growth was not completely inhibited (Fig. 7, I–K), as
reported previously (10, 11). PREX1 knockdown tumors
exhibited reduced numbers of proliferating cells by Ki-67
staining (Fig. 7, L and M) and reduced phosphorylated
ERK1/2 antibody staining (Fig. 7, L and N).
Discussion
PREX1 is a critical effector of ErbB2/3 signaling in breast
cancer (10, 11). PREX1 expression is essentially undetectable in
normal human mammary epithelial tissue but is significantly
up-regulated in human breast carcinomas, specifically the ER
luminal subtype (10, 11). The mechanisms underlying PREX1
promotion of cell proliferation and transformation are still
emerging. Although several studies have examined the effects
of PREX1 shRNA knockdown on cell proliferation, anchorage-
FIGURE 5. PREX1 regulates staurosporine/tamoxifen-induced apoptosis. A, stable MDA-MB-231-luc-D3H1 cells expressing control vector or HA-PREX1
were treatedwith 1M staurosporine for 16 h. Apoptotic cells were identified using a TUNEL assay. Data are presented asmean -fold change in TUNEL-positive
cells S.E. relative to control vector, which was assigned an arbitrary value of 1 (n 3). B, stable MDA-MB-231-luc-D3H1 cells expressing control vector or
HA-PREX1 treated with DMSO vehicle or 1M staurosporine for 6 h were lysed and immunoblotted using PREX1, caspase 3, cleaved-caspase 3 (Asp175), PARP,
or-actin antibodies. C andD, data are presented asmean -fold change in cleaved caspase-3/uncleaved caspase-3 (C) or cleaved PARP/uncleaved PARP (D)
S.E. relative to control vector, which was assigned an arbitrary value of 1 (n 3). E, MCF-7-luc-F5 cells expressing control shRNA, PREX1 shRNA (1), or PREX1
shRNA (2) were treated with 1 M staurosporine for 16 h. Apoptotic cells were identified using a TUNEL assay. Data are presented as mean -fold change in
TUNEL-positive cells S.E. relative to control shRNA, whichwas assigned an arbitrary value of 1 (n 3). F, stableMCF-7-luc-F5 cells expressing control shRNA,
PREX1 shRNA (1), or PREX1 shRNA (2) treated with DMSO vehicle or 1 M staurosporine for 6 h were lysed and immunoblotted using PREX1, PARP, or -actin
antibodies.G, data arepresentedasmean -fold change in cleavedPARP/uncleavedPARPS.E. relative to control shRNA,whichwas assignedanarbitrary value
of 1 (n 3). H, stable MCF-7-luc-F5 cells expressing control shRNA, PREX1 shRNA (2), PREX1 shRNA (2) HA-PREX1, PREX1 shRNA (2) HA-4P-PREX1, PREX1
shRNA (2) HA-4P-PREX1, or PREX1 shRNA (2) GEF-dead HA-PREX1 were treated with 1 M staurosporine for 16 h. Apoptotic cells were identified using a
TUNEL assay. Data are presented asmean -fold change in TUNEL-positive cells S.E. relative to control shRNA, whichwas assigned an arbitrary value of 1 (n
3). I, stable MCF-7-luc-F5 cells expressing control shRNA, PREX1 shRNA (1), or PREX1 shRNA (2) were treated with 3M tamoxifen for 16 h. Apoptotic cells were
identified using a TUNEL assay. Data are presented as mean -fold increase in TUNEL-positive cells  S.E. relative to control shRNA, which was assigned an
arbitrary value of 1 (n 3). *, p	 0.05; **, p	 0.01; ***, p	 0.001.
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FIGURE 6. PREX1-regulated anchorage-independent cell growth and cell migration is dependent on ERK1/2 activity. A, stable MDA-MB-231-luc-D3H1
cells expressing control vector, HA-PREX1, or GEF-dead HA-PREX1 were grown in soft agar for 3–4 weeks. Representative images are shown. B, data are
presented as mean -fold change in colony number S.E. relative to control vector, which was assigned an arbitrary value of 1 (n 3). C, stable MDA-MB-231-
luc-D3H1 cells expressing control vector or HA-PREX1 were grown in soft agar with addition of 5 or 10M NSC23766 (Rac1 inhibitor) or DMSO vehicle.D, data
are presented as mean -fold change in colony number S.E. relative to vehicle-treated control vector, which was assigned an arbitrary value of 1 (n 4). E,
stableMDA-MB-231-luc-D3H1 cells expressing control vector or HA-PREX1with addition of 1MU0126 (MEK1/2 inhibitor) or DMSOvehiclewere grown in soft
agar. F, data are presented asmean -fold change in colony number S.E. relative to control vector, whichwas assigned an arbitrary value of 1 (n 3).G, stable
MCF-7-luc-F5 cells expressing control shRNA, PREX1 shRNA (2), PREX1 shRNA (2) HA-PREX1, or PREX1 shRNA (2) GEF-dead HA-PREX1 were grown in soft
agar. H, data are presented as mean -fold change in colony number S.E. relative to control shRNA, which was assigned an arbitrary value of 1 (n 3). I, the
migration capacity of stable MDA-MB-231-luc-D3H1 cells expressing control vector or HA-PREX1 pretreated with DMSO vehicle or 20M U0126 was assessed
by Transwell assay. Cells were allowed tomigrate toward 10% FCS-containing growthmedium. J, data are presented asmean -fold change inmigrated cells
S.E. relative to vehicle-treated control vector, which was assigned an arbitrary value of 1 (n 3). *, p	 0.05; **, p	 0.01; ***, p	 0.001. Scale bar 200 m.
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independent cell growth, and xenograft formation (10, 11, 19,
40), our study is the first to show that ERK1/2 is a critical down-
streammediator of PREX1 oncogenicity in breast cancer. Here
we report increased PREX1 expression promotes ERK1/2 phos-
phorylation, breast cancer cell proliferation, anchorage-inde-
pendent cell growth, and xenograft tumor growth. In addition,
PREX1 regulates apoptosis in response to staurosporine and,
more significantly, the anti-estrogen drug tamoxifen. Although
several studies have shown that PREX1 promotes ERK1/2 sig-
naling in breast cancer cells (19, 40), evidence that this is a
mechanism for its oncogenicity has not been shown. As
reported here, inhibition of ERK1/2 signaling suppresses
PREX1-driven anchorage-independent cell growth, cell migra-
tion, and inhibition of apoptosis. Furthermore, in a series of
reconstitution experiments, we demonstrate that PREX1-me-
diated ERK1/2 activation and anchorage independent cell
growth are critically dependent on PREX1 Rac-GEF activity.
PI3K-generated PtdIns(3,4,5)P3 positively regulates PREX1
activation, which, in turn, activates AKT and ERK signaling in a
positive feedback loop (5, 8, 19). In addition, the PI3K-activated
Rac/PAK signaling pathway positively regulates theRaf-MEK1/
2-ERK1/2 signaling cascade. Rac/PAK enhances ERK1/2 acti-
vation in breast cancer cells in response to prolactin stimulation
in a PI3K-dependent but AKT-independent manner (41). Sev-
eral models have proposed that PI3K activates PREX1, which,
in turn, activates Rac/PAK, leading to the activation of ERK1/2
(19, 40), although the direct link betweenPREX1, Rac/PAK, and
ERK1/2 signaling is yet to be established in breast cancer. As
reported here, overexpression of PREX1 in breast cancer cells
significantly enhanced ERK1/2 phosphorylation and the
expression of its downstream effectors cyclinD1 and p21WAF1/CIP1
but not phosphorylation of AKT. We also demonstrated
PREX1 enhanced anchorage-independent cell growth in a
Rac1- and MEK1/2-ERK1/2-dependent manner. PREX1-regu-
lated cell proliferation was associated with the induction of
cyclin D1 and p21WAF1/CIP1 expression. In general, cyclin D1 is
regarded as oncogenic because of its role in promoting cell cycle
progression through the G1-S phase transition (42), whereas
p21WAF1/CIP1 is a well established negative regulator of cell
cycle progression (43). However, accumulating evidence sug-
gests that p21WAF1/CIP1 can positively regulate cell proliferation
by protecting the degradation of cytoplasmic cyclin D1, leading
to cyclin D1 retention in the nucleus and its association with
cyclin-dependent kinase Cdk4/6 (44–46). A recent report has
shown that Rac1 and ERK1/2-mediated breast cancer cell pro-
liferation is associatedwith increased cyclinD1 andp21WAF1/CIP1
protein expression following heregulin stimulation (21). There-
fore, PREX1 regulation of cyclin D1 and p21WAF1/CIP1 expres-
sionmay depend on Rac1 and ERK1/2 activation; however, fur-
ther investigation is required.
Here we showed that PREX1 overexpression or its shRNA
knockdown in breast cancer cells did not significantly affect
AKT phosphorylation/activation in response to EGF or IGF-1
stimulation. This is consistent with previous reports that AKT
phosphorylation was not regulated by PREX1 following EGF,
heregulin, or TGF stimulation of human breast cancer cells
(10). Nevertheless, we cannot exclude the possibility that
PREX1 regulates AKT activation in other cancer cell types, as
there is evidence that PREX1 promotes AKT phosphorylation
via Rac1 in ovarian cancer cells (47), and a recent report showed
that PREX1promotesAKTphosphorylation in ER breast can-
cer cells following IGF-1 stimulation (19).We observed a trend
towardPREX1-regulatedAKTactivation, and it is possible that,
with high agonist concentration, a more sustained activation of
AKT may be observed.
Decreased xenograft mammary tumor growth has been
described using PREX1 shRNA in several breast cancer cell
lines (10, 11), as also reported in this study. However, PREX1
expression is increased in human breast cancers, and no study
has addressed whether overexpression of PREX1 in vivo can
recapitulate these observations. Here we demonstrated, in a
xenograft mouse model, that overexpression of wild-type but
not GEF-dead PREX1 in MDA-MB-231-luc-D3H1 cells
resulted in significantly larger tumors relative to control cells.
In addition, tumors overexpressing PREX1 exhibited increased
cell proliferation and reduced apoptosis and showed evidence
of enhanced activation of ERK1/2 but not AKT, as demon-
strated by phosphoimmunohistochemistry.
The Raf/MEK/ERK cascade is a key signaling pathway
involved in regulating cell proliferation, survival, andmigration
(48); therefore, much attention has been focused on developing
inhibitors of this signaling pathway. Not surprisingly, many of
the available MEK inhibitors exhibit antitumor activity in
human xenograft models of breast cancer, and some are cur-
rently undergoing phase I/II clinical trials (49, 50). It is tempting
to speculate that breast cancers with PREX1 overexpression
may benefit from therapeutic intervention of the Raf/MEK/
ERK signaling pathway, although further studies are required to
FIGURE 7. PREX1 promotes tumor growth and ERK1/2 phosphorylation in xenograft mouse models. A, MDA-MB-231-luc-D3H1 cells stably transduced
with control vector, HA-PREX1, or GEF-dead HA-PREX1 were analyzed by immunoblotting using HA, PREX1, or GAPDH antibodies. B, stable MDA-MB-231-luc-
D3H1 cells expressing control vector, HA-PREX1, orGEFdeadHA-PREX1were injected into themammary fat padsof BALB/cnu/numice, and tumorgrowthwas
analyzed by caliper measurement. C, measurement of tumor size over 23 days. The mean tumor volume S.E. of seven (control vector, GEF dead HA-PREX1)
or eight (HA-PREX1) individual animals per group is shown.D, mean tumor volumes 15, 18, and 23 days post-injection indicate that HA-PREX1-overexpressing
cells form larger tumors in vivo. E, control vector andHA-PREX1 tumorswere immunostainedusingKi-67, cleavedcaspase-3, pERK1/2, orpAKTSer-473 antibodies.
Scale bar  100 m. F and G, data represent the average percentage of Ki-67-positive (F) or cleaved caspase-3-positive cells (G)  S.E. 5 fields/tumor were
examined, and 5 animals/group were analyzed. H, the number of pERK1/2-positive points per field of 5 fields/tumor was determined and expressed as a
percentage of total points per field. Data represent the average percentage of pERK1/2-positive points per field S.E. 5 animals/groupwere analyzed. I, stable
MCF-7-luc-F5 cells expressing control shRNA or PREX1 shRNA (2) were injected into the mammary fat pads of BALB/c nu/nu mice, and tumor growth was
analyzed by caliper measurement. J, photograph of tumors extracted 8.5 weeks post-injection shows that PREX1 shRNA (2) cells formed smaller tumors
comparedwith control shRNA cells. Scale bar 1 cm. K, measurement of tumor size over 8.5weeks. Themean tumor volume S.E. of seven control shRNAand
eightPREX1 shRNA (2) tumors is shown. L, control shRNAorPREX1 shRNA (2) tumorswere immunostainedusingKi-67orpERK1/2antibodies. Scale bar50m.
M, data represent the average percentage of Ki-67-positive cells S.E. 5 fields/sample were examined, and seven control shRNA and eight PREX1 shRNA (2)
tumorswere analyzed.N, the number of pERK1/2-positive points per field of 5 fields/tumorwere determined and expressed as a percentage of total points per
field. Data represent the averagepercentage of pERK1/2-positive points per field S.E. Seven control shRNAandeight PREX1 shRNA (2) tumorswere analyzed.
*, p	 0.05; **, p	 0.01; ***, p	 0.001.
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evaluate these inhibitors in mouse breast cancer models with
PREX1 overexpression.
Recentlywe reported the 1.95-Å x-ray crystal structure of the
PREX1 DH-PH domain in complex with its canonical GTPase,
Rac1 (51). Using structure-guided mutagenesis, we dissected
the critical role the PREX1 DH domain-Rac1 interface plays in
promoting Rac1 activation both in vitro and downstream of
G-protein-coupled receptor and receptor tyrosine kinase sig-
naling in breast cancer cell lines (51). Here we demonstrated
that the PREX1 DH-PH domain is also critical in mediating
PREX1 anchorage-independent cell growth and inhibition of
apoptosis. Other domains, such as the IP4P domain, exhibit no
activity in this context. Notably, PREX1-mediated cell growth/
survival under anchorage-independent conditions and xeno-
graft tumor growth are dependent on its ability to activate Rac,
suggesting that regulation of this signaling pathway may be a
potential mechanism for targeted therapies for PREX1-positive
tumors.
Experimental Procedures
Cell Lines and Antibodies—MCF-7-luc-F5 (MCF-7 human
mammary adenocarcinoma cells stably transfected with the
North American firefly luciferase gene expressed from a CMV
promoter) and MDA-MB-231-luc-D3H1 (MDA-MB-231
humanmammary adenocarcinoma cells stably transfectedwith
the North American firefly luciferase gene expressed from an
SV40 promoter) breast cancer cell lines were purchased from
Caliper Life Sciences (PerkinElmer Life Sciences).
Antibodies for ERK1/2 (4695), pERK1/2 (9106), -actin
(4970), AKT (4685), pAKTThr-308 (4056), pAKTSer-473 (4058),
caspase-3 (9665), cleaved caspase-3 (Asp157, 9664) and PARP
(9532) were purchased from Cell Signaling Technology (Bos-
ton, MA). Ki-67 (RM-9106-S0) and GAPDH (AM4300) anti-
bodies were purchased from Thermo Fisher (Waltham, MA).
Monoclonal HA antibody (MMS-101R) was purchased from
Covance (Princeton, NJ). PREX1 antibodies were generated in-
house and purified against recombinant EE-PREX1 protein.
Cell Culture and Lentiviral Transductions—MDA-MB-231-
luc-D3H1 cells were maintained in DMEM (Gibco, Life Tech-
nologies) supplemented with 10% FBS (Gibco, Life Technolo-
gies), 100 units/ml penicillin, 1% (v/v) streptomycin, and 2 mM
L-glutamine (JRH Biosciences, St. Louis, MO). MCF-7-luc-F5
cells were maintained as described above with addition of 10
g/ml human insulin (Sigma-Aldrich). Heterogeneous pools of
MDA-MB-231-luc-D3H1 cells stably expressing HA-PREX1,
GEF-dead HA-PREX1, or control vector (mCherry) were gen-
erated by transduction with lentiviral particles carrying the
plasmid pHIV-1SDmCMVmCherry.pre encoding control vec-
tor alone, HA-PREX1, or GEF-dead HA-PREX1. Heterogene-
ous pools of PREX1 knockdown MCF-7-luc-F5 cells were gen-
erated by transducing non-target shRNA or two shRNA
sequences targeting two distinct regions of PREX1mRNA (Sig-
ma-Aldrich, St. Louis, MO). Clones were selected in complete
medium containing 1 g/ml puromycin for 1 week and then
maintained in 0.5 g/ml of puromycin. Heterogeneous pools
of PREX1 knockdown MCF-7-luc-F5 cells stably expressing
lentiviral particles carrying the plasmid pHIV-1SDmCMVm-
Cherry.pre encoding HA-PREX1, 4P-PREX1, 4P-PREX1, or
GEF-dead-PREX1 were generated as described above.
Western Blotting—For EGF or IGF-1-stimulation assays, cells
were serum-starved for 24 h before stimulation with 100 ng/ml
EGF (BD Biosciences) or 10 ng/ml IGF-1 (Sigma-Aldrich).
MCF-7-luc-F5 cells were serum-starved in phenol-red free
DMEM (Gibco, Life Technologies). Cells were lysed in SDS-
PAGE sample buffer (62.5mMTris-HCl (pH6.8), 2% (w/v) SDS,
10% glycerol, 50 mM DTT, and 0.01% (w/v) bromphenol blue).
To analyze the protein expression of cleaved caspase-3 or
PARP, cells were treated with 1 M staurosporine (Cell Signal-
ing Technology) for 6 h and then lysed with ice-cold lysis buffer
(1% Triton X-100, 20mMTris-HCl (pH 7.4), 150mMNaCl, and
a protease mixture tablet (Roche)). Equal amounts of total pro-
tein were separated by 10% SDS-PAGE followed by immuno-
blotting, and then signals were visualized by ECL (PerkinElmer
Life Sciences). Commercially available antibodies were used at
dilutions according to the recommendations of the manufac-
turer. In-house affinity-purified polyclonal PREX1 antibodies
were used at 1:1000.
Soft Agar Assay—6
 103 cells were resuspended in DMEM/
10% FBS/0.3% agar with addition of 1MU0126 (Cell Signaling
Technology), 5 or 10 M NSC23766 (Tocris Bioscience), or
DMSO over a base composed of DMEM/10% FBS/0.7% agar in
6-well dishes in triplicate for each experiment. Cells were incu-
bated for 3–4 weeks at 37 °C, and then colonies were imaged
using a Leica M165C stereomicroscope and a Leica DFC295
camera.
In Vitro Cell Proliferation Assays—For MTT assays, equal
numbers of cells were seeded into 96-well plates and incubated
for 0, 24, 48, or 72 h. Cell proliferation assays were performed
using theCell ProliferationKit I (MTT, Roche) according to the
instructions of the manufacturer.
TUNEL Assay—Apoptosis was induced by addition of 1 M
staurosporine (Cell Signaling Technology) or 3 M tamoxifen
(Sigma-Aldrich) to complete medium for 16 h. Cells were fixed
with 3–4% paraformaldehyde for 1 h. Apoptotic cells were
identified using the In Situ Cell Death Detection Kit, Fluores-
cein (Roche) according to the instructions of themanufacturer.
Five random fields per coverslip were imaged, and250 cells/
coverslip were counted.
Orthotopic Xenograft Implantation—All experimental pro-
cedures involving mice were approved by the Animal Ethics
Committee at theMonashUniversity School of Biomedical Sci-
ences (SOBS/2008/14 or MARP/2013/132). A total of 1 
 106
cells suspended in 15l of PBS plus 50% growth factor-reduced
Matrigel (BD Biosciences) were injected into the mammary fat
pads of 7- to 8-week-old female BALB/c nu/nu mice (Animal
Resources Centre, Australia). Mice injected with MCF-7-
luc-F5 cells were also implantedwith 90-day release, 1.7-mg/ml
E2 pellets (Innovative Research of America) under anesthesia.
The width and length of palpable tumors were measured with
digital calipers three times weekly. Tumor volume was calcu-
lated using the equation (length) x (width)2/2.
Immunohistochemistry—Xenograft tumors were excised,
fixed in 10% formalin overnight, and then paraffin-embedded.
Tumor sections were deparaffinized in three changes of xylene,
rehydrated through three changes of ethanol, and then sub-
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jected to heat-induced antigen retrieval for 10 min in EDTA
(pH 9.0). Tumor sections were blocked with 1% BSA before
incubationwith p-ERK1/2, cleaved caspase-3 (Asp175), or Ki-67
antibodies diluted in 1% BSA at 4 °C overnight. Primary anti-
bodies were used at dilutions according to the recommenda-
tions of the manufacturer. Immunoreactivity was detected
using the EnVision HRP-3,3-diaminobenzidine system
(Dako, Glostrup, Denmark) according to the instructions of the
manufacturer. Coverslips were mounted using D.P.X. (Sigma-
Aldrich). 3,3-diaminobenzidine staining of p-ERK1/2 was
quantified by counting the p-ERK1/2-positive points of five dif-
ferent fields/tumor using ImageJ analysis software.
Boyden Chamber Migration Assay—Cell migration assays
were performed using 6.5-mm Transwells with 8.0-m pore
polycarbonate membrane inserts (Corning). Cells were serum-
starved for 48 h before being seeded in the upper chamber in
serum-free medium containing DMSO or U0126 for 5 h at
37 °C. Completemediumwas placed in the lower compartment
as a chemoattractant. After incubation, non-migrated cells
were wiped off from the upper surface with a cotton swab, and
migrated cells on the lower surface were fixed and stained using
the DiffQuick staining kit (Lab Aids Pty Ltd., Narrabeen, Aus-
tralia). All migrated cells were counted and quantified using
ImageJ analysis software.
Statistical Analysis—All Statistical analyses were performed
using GraphPad Prism 5.0 by unpaired Student’s t test or one-
way analysis of variance followed by Dunnett’s post-test. p 	
0.05 was considered statistically significant.
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formulated the hypotheses, designed the experiments, and analyzed
the data. The manuscript was written by H. J. L. and C. A. M. and
edited by all authors.
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